Early-Stage Life Science Investors at RESI

By Love Chung, Investor Research Analyst, LSN

Calling all actively investing in early-stage life sciences! At RESI, you will have the opportunity to connect with a diverse array of innovative entrepreneurs, promising startups, and seasoned industry leaders. This conference will provide an invaluable snapshot of the latest trends, breakthrough technologies, and investment opportunities that are reshaping the future of healthcare. Early-stage companies attending from the biotech, medtech, diagnostic and digital health sectors. Don’t miss out on this unparalleled platform to leverage your expertise and drive transformative advancements in life sciences investment.

Below are a few testimonials from investors who have attended RESI Boston this past June:

“It is our second year at RESI. In 3 days, I opened my schedule to global organizations and met efficiently online over 55 quality life sciences and medical device companies. Some are now part of our Keiretsu portfolio. I love collaborating with RESI and sourcing possible deals for our Investors’ chapters”

Daniela Tixi, Keiretsu Forum Canada

“I have been attending the RESI since 2018, and I find it very useful in that it allows me to meet with many startup companies that I would not be able to meet at partnering conferences such as BIO International. In fact, I often attend smaller partnering conferences as well as BIO International, but there are a few startup companies that we could only meet at RESI because we could not meet them at those partnering conferences, which is a true testament to the value of RESI. I also benefit from the information on cutting-edge drug discovery research and technology that we can gain from participating in RESI. In addition, it is very beneficial from a long-term perspective that RESI offers a chance for startup companies to join RESI so that they can build partnerships with pharmaceutical companies or VC firms and become our future collaboration partners. From this perspective, I hope that startup will continue to participate in RESI and deepen its collaboration with us and other pharmaceutical companies and VCs who are also participating in RESI to build the ecosystem.”

Hiroyuki Eda, EA Pharma

“We came to RESI as potential investors, and unexpectedly found many more companies representing significant early-stage opportunities for investment and partnership. The atmosphere was extremely collegial with a chance to meet multiple times within the venue. I participated as a judge on a cell and gene therapy pitch session panel, and also enjoyed giving feedback to the companies who pitched there, plus got to know some of the other judges after the panel event. This was another unexpected plus to attending the RESI meeting. I strongly recommend this meeting to others.”

Barri Blauvelt, Tamer Group

Hear from more investors and view confirmed investors at RESI!